Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ 2 Stocks I Like Better Than Constellation Software at Today’s Price (Fool) +++ CONSTELLATION SOFTWARE Aktie +3,15%

NRX PHARMACEUTICALS Aktie

 >NRX PHARMA Aktienkurs 
2.46 EUR    -1.6%    (Tradegate)
Ask: 2.56 EUR / 1945 Stück
Bid: 2.46 EUR / 2045 Stück
Tagesumsatz: 210 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
NRX PHARMA Aktie über LYNX handeln
>NRX PHARMA Performance
1 Woche: +4,8%
1 Monat: +18,2%
3 Monate: -11,0%
6 Monate: +41,3%
1 Jahr: 0%
laufendes Jahr: 0%
>NRX PHARMACEUTICALS Aktie
Name:  NRX PHARMACEUTICALS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US6294442099 / A4091K
Symbol/ Ticker:  B1Q (Frankfurt) / NRXP (NASDAQ)
Kürzel:  FRA:B1Q, ETR:B1Q, B1Q:GR, NASDAQ:NRXP
Index:  -
Webseite:  https://www.nrxpharma.com..
Profil:  NRX Pharmaceuticals Inc. is a biopharmaceutical co..
>Volltext..
Marktkapitalisierung:  60.56 Mio. EUR
Unternehmenswert:  66.8 Mio. EUR
Umsatz:  -
EBITDA:  -12.04 Mio. EUR
Nettogewinn:  -28.79 Mio. EUR
Gewinn je Aktie:  -1.91 EUR
Schulden:  8.72 Mio. EUR
Liquide Mittel:  2.48 Mio. EUR
Operativer Cashflow:  -9.35 Mio. EUR
Bargeldquote:  0.07
Umsatzwachstum:  -
Gewinnwachstum:  -36.16%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  NRX PHARMACEUTICALS, NRX PHARMA, NRX PHARMACEUTICAL
Letzte Datenerhebung:  26.09.25
>NRX PHARMA Kennzahlen
Aktien/ Unternehmen:
Aktien: 23.77 Mio. St.
Frei handelbar: 87.84%
Rückkaufquote: -6.31%
Mitarbeiter: -
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 1003.68%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: -
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -669.06%
Eigenkaprendite: -
>NRX PHARMA Peer Group

Es sind 600 Aktien bekannt.
 
24.09.25 - 16:18
NRx Pharmaceuticals gets FDA approval for suitability petition of Ketafree (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
24.09.25 - 15:30
New to The Street′s Prestigious Client NRx Pharmaceuticals, Inc. Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx′s Proposed Strength of Preservative-Free Ketamine (Accesswire)
 
Suitability Petition is required for shift from multidose packaging of ketamine to single-patient dose preservative free ketamineGranting of Suitability Petition enables re-filing of Abbreviated Ne......
24.09.25 - 14:06
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx′s Proposed Strength of Preservative-Free Ketamine (GlobeNewswire EN)
 
WILMINGTON, Del., Sept. 24, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, announced that it was notified yesterday by the United States Food and Drug Administration that a Suitability Petition has been granted for the strength proposed by the Company for its planned single-patient, preservative-free ketamine product (KETAFREE™). Currently, ketamine is sold in multi-dose vials that contain Benzethonium Chloride, a toxic preservative. The Suitability Petition that has been granted enables immediate re-filing of the Company's Abbreviated New Drug Application for KETAFREE™. The Company believes that this proposed product addresses two critical policy objectives as articulated by the current administration: (1) the re-shoring of strategically important drugs, particularly sterile products from foreign manufacturing sources, and (2) the “Make America Healthy Again” (MAHA) objective of removing toxic preservatives and colorants from foods...
08.09.25 - 14:21
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics (GlobeNewswire EN)
 
MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- HOPE Therapeutics™, Inc. ("HOPE"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced the closing of the previously announced acquisition of Dura Medical (Dura). Dura, together with the pending Neurospa TMS and Cohen and Associates acquisitions, are planned to provide a comprehensive service offering to patients at more than 8 locations along the West Coast of Florida. Dura is revenue generating and EBITDA positive....
03.09.25 - 14:06
NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright′s 27th Annual Global Investment Conference on Monday, September 8th (GlobeNewswire EN)
 
WILMINGTON, Del., Sept. 03, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, today announced that Jonathan Javitt, M.D., M.P.H., Chairman and Chief Executive Officer of NRx Pharmaceuticals, will participate in a fireside chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8, 2025, from 4:30 to 5:00 PM ET....
02.09.25 - 19:24
UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller, Sponsored by Rockefeller Global Family Office (GlobeNewswire EN)
 
SOUTHAMPTON, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, presented two keynote talks to a gathering of leading family offices and family members sponsored by the Global Passion Project and the Rockefeller Global Family Office on August 28-30, 2025 in Southampton, NY. The Company's CEO, Prof. Jonathan Javitt, MD, MPH spoke alongside Matthew Rockefeller, Bradley Hilton and Cheryl Young of Rockefeller Capital, and representatives of leading family offices to detail plans for the Fall 2025 launch of HOPE Therapeutics clinics and a prospective unique one-week residential program targeting suicidal depression, PTSD, traumatic brain injury, and cognitive dysfunction. The HOPE residential program will be the nation's first to combine neuroplastic drugs, including ketamine, transcranial magnetic stimulation and hyperbaric oxygen therapy in a campus-like setting that adds nutritional therapy from one of the nation's leading chefs...
02.09.25 - 14:45
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital (GlobeNewswire EN)
 
SOUTHAMPTON, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, presented two keynote talks to a gathering of leading family offices and family members sponsored by the Global Passion Project and Rockefeller Capital on August 28-30, 2025 in Southampton, NY. The Company's CEO, Prof. Jonathan Javitt, MD, MPH spoke alongside Matthew Rockefeller, Bradley Hilton and Cheryl Young of Rockefeller Capital, and representatives of leading family offices to detail plans for the Fall 2025 launch of HOPE Therapeutics clinics and a prospective unique one-week residential program targeting suicidal depression, PTSD, traumatic brain injury, and cognitive dysfunction. The HOPE residential program will be the nation's first to combine neuroplastic drugs, including ketamine, transcranial magnetic stimulation and hyperbaric oxygen therapy in a campus-like setting that adds nutritional therapy from one of the nation's leading chefs, neuroplastic-ta...
29.08.25 - 19:54
New to The Street T.V. Broadcasting on Bloomberg Saturday Aug 30th. The episode features TON Strategy Company, Laser Photonics, Sullivan & Cromwell Senior M&A Partner Frank Aquila, and Mercurity Fintech (Accesswire)
 
Sponsored TV commercials by NRx Pharma (NASDAQ:NRXP), Synergy CHC (NASDAQ:SNYR), ACURX Pharmaceuticals (NASDAQ:ACXP), and Sustainable Green Team (OTCQX:SGTM). NEW YORK CITY, NEW YORK / ACCESS Newsw......
27.08.25 - 14:06
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine) (GlobeNewswire EN)
 
WILMINGTON, Del., Aug. 27, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, today announced its expanded access policy for NRX-100 (preservative-free ketamine) based on grant of Fast Track designation for NRX-100 in the treatment of suicidal ideation in patients with depression, including bipolar depression....
20.08.25 - 18:30
NRx Pharmaceuticals outlines expanded fast track for NRX-100 and targets $750M ketamine market following balance sheet strengthening (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
19.08.25 - 07:54
NRx Pharmaceuticals reports Q2 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
14.08.25 - 00:09
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025 (PR Newswire)
 
Conference Call 8:00am ET, Wednesday August 20, 2025 WILMINGTON, Del., Aug. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025......
11.08.25 - 15:30
New to The Street Client NRx Pharmaceuticals Secures FDA Fast Track Designation for NRX-100, Expanding Reach to 13 Million Americans Confronting Suicidal Ideation (Accesswire)
 
NEW YORK, NY / ACCESS Newswire / August 11, 2025 / New to The Street proudly spotlights its esteemed client, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), which today announced that the U.S. Food and Dr......
11.08.25 - 14:06
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression (PR Newswire)
 
This designation expands the addressable population for NRX-100 to the 13 million Americans who consider suicide each year and represents a 10x expansion of the addressable population compared to the Designation granted in 2017 for bipolar depression alone The Designation includes an FDA......
09.08.25 - 19:06
New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals (Accesswire)
 
NEW YORK CITY, NY / ACCESS Newswire / August 9, 2025 / New to The Street, one of the nation's longest-running business television brands, will broadcast Show #683 on Bloomberg today at 6:30 PM EST.......
08.08.25 - 14:06
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida′s Agency for Health Care Administration (AHCA) (PR Newswire)
 
Florida's Agency for Health Care Administration (AHCA) approval is a critical regulatory step toward closing the Dura Medical acquisition Dura Medical, together with previously-announced acquisitions of Neurospa TMS, and Cohen and Associates, to provide coverage along the West Coast of......
04.08.25 - 14:06
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of a Citizen Petition with the US Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products (PR Newswire)
 
Sterile ketamine products currently for sale in the United States contain benzethonium chloride, a preservative with known toxicity that is not Generally Recognized as Safe and Effective by the US Food and Drug Administration FDA has previously prohibited the use of benzethonium chloride......
01.08.25 - 16:42
New to The Street Show #682 Premieres on Bloomberg Tonight Featuring Industry Leaders: DataVault, PetVivo, Health In Tech, FLOKI, and NRx Pharma Backed by National TV Commercials and Outdoor Campaigns Sponsored by MUSQ, ArriveAI, and Sustainable Gree (Accesswire)
 
Backed by National TV Commercials and Outdoor Campaigns Sponsored by MUSQ, ArriveAI, and Sustainable Green Team NEW YORK CITY, NEW YORK / ACCESS Newswire / August 1, 2025 / New to The Street, the n......
29.07.25 - 14:06
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join Fireside Chat at BTIG Virtual Biotech Conference July 29 - 30, 2025 (PR Newswire)
 
WILMINGTON, Del., July 29, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), today announced that its CEO and Chairman will join a fireside chat at BTIG Virtual Biotechnology Conference on July 29 – 30, 2025. Prof. Jonathan Javitt,......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Aus der Wurzel der Schlange wird eine Viper wachsen, und ihre Frucht wird ein fliegender Drache sein. - Altes Testament: Jesaja
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!